Table 2 Specific EZH2 inhibitors in lymphoid malignancies
From: EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
Inhibitor(s) | Malignancies | Authors |
|---|---|---|
GSK126 | EZH2-mutant and wild-type GC-DLBCL, FL, ABC-DLBCL, T-ALL, MCL, ATLL, CTCL, MM | Xu L., et al. [122]; Lue JK., et al. [123]; Adamik J., et al. [124]; Zeng D., et al. [125]; Ott HM., et al. [126]; McCabe MT., et al. [35] |
GSK343 | MM | Ezponda T., et al. [127] |
EI1 | EZH2-mutant GC-DLBCL | Qi W., et al. [128] |
EPZ-6438 | EZH2-mutant and wild-type GC-DLBCL, MM | Herviou L., et al. [129]; Dimopoulos K., et al. [130]; Brach D., et al. [131]; Knutson SK., et al. [132] |
EPZ005687 | EZH2-mutant and wild-type GC-DLBCL | Knutson SK., et al. [133] |
EPZ011989 | EZH2-mutant GC-DLBCL | Campbell JE., et al. [134] |
EBI-2511 | EZH2-mutant GC-DLBCL | Lu B., et al. [135] |
ZLD10A | EZH2-mutant GC-DLBCL | Song X., et al. [136] |
DCE_42/254 | EZH2-mutant and wild-type GC-DLBCL | Wu Y., et al. [137] |
CPI-1205 | EZH2-mutant GC-DLBCL | Vaswani RG., et al. [138] |
Tetramethyl-piperidinyl Benzamides | EZH2-mutant GC-DLBCL | Nasveschuk CG., et al. [139] |